R&D News | pharmaphorum

News

Nasdaq debutante Septerna swells its IPO to $331m

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.

News

Alpha-9's $175m third-round heads latest biotech financings

Radiopharma start-up Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth The

News

AZ confirms its China president is under investigation

The head of AstraZeneca's Chinese operations has been placed under investigation by the authorities in Beijing, although the reasons for the probe remain unclear.

News

Eledon drug helps transplants 'cure' type 1 diabetes

Eledon Pharmaceuticals has revealed that two patients with type 1 diabetes achieved a 'functional cure' after receiving a transplant of insulin-producing islet cells in combination with its

News

Lilly touts new Kisunla regimen that reduces side effects

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions f

News

Pfizer rebuffs Starboard criticism as it raises forecasts

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c

Nasdaq debutante Septerna swells its IPO to $331m

Alpha-9's $175m third-round heads latest biotech financings

AZ confirms its China president is under investigation

Eledon drug helps transplants 'cure' type 1 diabetes

Lilly touts new Kisunla regimen that reduces side effects

Pfizer rebuffs Starboard criticism as it raises forecasts

Precision medicine in action, with Cary Claiborne

How to meet your physicians where they are online

News

Editor's Picks